Guardian Pharmacy Services Stock Earnings Reports

Key points for investors: Guardian reported solid Q1 2026 results while navigating the new IRA pharmacy framework. Reported revenue was $336.6M, up 2% year-over-year (would have been low double-digit growth absent mandated IRA price declines). Gross profit was $76.0M, up 19% year-over-year (14% ex a $3M discrete benefit); reported gross margin 22.7% (22.0% ex the $3M benefit). Adjusted EBITDA was $29.8M, up 27% y/y (14% ex the $3M benefit) with an 8.8% margin (8.0% excluding the discrete benefit). Management updated full-year adjusted EBITDA guidance to $123M–$127M (from $120M–$124M); revenue guidance remains $1.40B–$1.42B. The IRA materially reduced branded drug pricing (management cites ~60% decline for impacted branded mix), introduced more complex transaction/payment flows and a one-time working capital timing shift; management says these effects were largely anticipated and are manageable given Guardian’s scale and balance sheet. The quarter included discrete items: ~ $3M favorable payer/manufacturer items that flow to adjusted EBITDA, $3.2M legal expense (added back in adjusted EBITDA), and a subsequent $8.5M cash settlement to be recognized as other income in Q2 (not included in adjusted EBITDA). Cash ended the quarter at ~$65M with minimal debt; management intends to continue M&A at a steady pace (robust pipeline) and has completed a nondilutive secondary offering (6.9M shares at $31). Key near-term risks: potential fuel-price volatility (could be a few-million-dollar headwind annually), modestly higher labor costs as the company invests in regional leadership, and legislative uncertainty around IRA-related relief. Management emphasizes scale advantages, successful renegotiations with payors to mitigate IRA impacts, continued organic growth (residents and scripts +10% y/y), and confidence in execution while remaining disciplined.